Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,130.00GBp
15 Jan 2018
Change (% chg)

-- (--)
Prev Close
5,130.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,431,006
52-wk High
5,585.07
52-wk Low
4,136.50

Latest Key Developments (Source: Significant Developments)

Astrazeneca Says ‍Fasenra Receives EU Approval
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Astrazeneca Plc ::‍FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA​.ASTRAZENECA - ‍FASENRA IS ALSO UNDER REGULATORY REVIEW IN JAPAN AND SEVERAL OTHER COUNTRIES, WITH EXPECTED REGULATORY DECISIONS IN H1 2018​.  Full Article

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Myriad Genetics Inc ::MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA.MYRIAD GENETICS INC - FINANCIAL TERMS WERE NOT DISCLOSED..MYRIAD GENETICS INC - UNDER AGREEMENT, MYRIAD WILL USE ITS MYCHOICE HRD PLUS TEST TO EVALUATE PATIENTS ENROLLED IN AN ONGOING PHASE III TRIAL.  Full Article

Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.  Full Article

Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain
Friday, 22 Dec 2017 

Dec 22 (Reuters) - ALMIRALL SA ::EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN).LICENSE AGREEMENT GRANTS ALMIRALL EXCLUSIVE RIGHTS TO COMMERCIALIZE CRESTOR AND PROVISACOR IN SPAIN.  Full Article

Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Astrazeneca Plc ::PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING.  Full Article

Chembio Diagnostics And Astrazeneca Collaborates To Develop Point-Of-Care Diagnostic Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Astrazeneca Plc ::CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST.CHEMBIO DIAGNOSTICS INC - UNDER TERMS OF 18-MONTH AGREEMENT, CO WILL RECEIVE UP TO $2.9 MILLION IN FUNDING FROM ASTRAZENECA.  Full Article

US FDA Accepts Regulatory Submission For Tagrisso (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Astrazeneca Plc ::US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO (OSIMERTINIB) IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER.  Full Article

US FDA Accepts Tagrisso Submission For 1St-Line Nsclc
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Astrazeneca Plc ::FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC.‍US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​.  Full Article

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Photo

U.S. FDA approves expanded use of AstraZeneca cancer drug

The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.